NCT04090775
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma treatment 2 completed NCT02458716
Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer treatment 1 completed NCT03678025
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer treatment 3 recruiting NCT04085991
Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer No drug interventions treatment 2 terminated NCT03069937
Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer. No drug interventions treatment 2 active_not_recruiting NCT01253642
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel No drug interventions treatment 2 terminated NCT03827473
Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer No drug interventions treatment 2 terminated NCT02099864
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy No drug interventions treatment 2 active_not_recruiting NCT05733351
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer treatment 1 recruiting NCT03902951
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer treatment 2 active_not_recruiting NCT04685811
Evaluation of PSMA Antagonist Produced by Two Different Methods No drug interventions diagnostic 1 / 2 completed NCT06039371
Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study treatment 2 recruiting NCT05113537
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer treatment 1 / 2 recruiting NCT03611686
Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies No drug interventions Not Available Not Available recruiting NCT04781374
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer treatment 2 withdrawn NCT05573789
Tumor Molecular Profiling in Patients With Prostate Cancer No drug interventions Not Available Not Available completed NCT05156372
Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients No drug interventions treatment Not Available withdrawn NCT04455750
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy treatment 3 active_not_recruiting NCT05689021
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations treatment 2 recruiting NCT06145633
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer treatment 2 recruiting NCT04616547
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones No drug interventions treatment 2 terminated NCT04704505
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) No drug interventions treatment 2 recruiting NCT05479578
Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer No drug interventions treatment 1 recruiting NCT05445609
Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer No drug interventions treatment 2 suspended NCT04033432
sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer No drug interventions treatment 2 unknown_status NCT05168618
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial No drug interventions treatment 2 recruiting NCT05054296
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring No drug interventions supportive_care 2 recruiting NCT06236139
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer No drug interventions treatment 1 / 2 not_yet_recruiting NCT04754425
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer No drug interventions treatment 2 active_not_recruiting NCT04734730
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer No drug interventions treatment 2 recruiting NCT04471974
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer No drug interventions treatment 2 recruiting NCT05796973
Measuring Oncological Value of Exercise and Statin No drug interventions treatment 3 recruiting NCT03317392
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis No drug interventions treatment 1 / 2 active_not_recruiting NCT04190446
Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment No drug interventions treatment 2 active_not_recruiting NCT06470750
Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Advanced Prostate Cancer (CaP) No drug interventions Not Available Not Available recruiting